Unknown

Dataset Information

0

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.

ABSTRACT: High throughput screening and subsequent hit validation identified 4-isopropyl-3-(2-((1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a potent inhibitor of IDH1R132H. Synthesis of the four separate stereoisomers identified the (S,S)-diastereomer (IDH125, 1f) as the most potent isomer. This also showed reasonable cellular activity and excellent selectivity vs IDH1wt. Initial structure-activity relationship exploration identified the key tolerances and potential for optimization. X-ray crystallography identified a functionally relevant allosteric binding site amenable to inhibitors, which can penetrate the blood-brain barrier, and aided rational optimization. Potency improvement and modulation of the physicochemical properties identified (S,S)-oxazolidinone IDH889 (5x) with good exposure and 2-HG inhibitory activity in a mutant IDH1 xenograft mouse model.

SUBMITTER: Levell JR 

PROVIDER: S-EPMC5304300 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

High throughput screening and subsequent hit validation identified 4-isopropyl-3-(2-((1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a potent inhibitor of IDH1<sup>R132H</sup>. Synthesis of the four separate stereoisomers identified the (<i>S</i>,<i>S</i>)-diastereomer (<b>IDH125</b>, <b>1f</b>) as the most potent isomer. This also showed reasonable cellular activity and excellent selectivity vs IDH1<sup>wt</sup>. Initial structure-activity relationship exploration identified the key tol  ...[more]

Similar Datasets

Methylation profiling Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1
2016-09-01 | GSE85571 | GEO
Unknown Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
| S-EPMC6047033 | biostudies-literature
Unknown Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.
| S-EPMC6862338 | biostudies-literature
Unknown New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
| S-EPMC5155016 | biostudies-literature
Unknown In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
| S-EPMC9103411 | biostudies-literature
Unknown Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones as Novel Tubulin Inhibitors.
| S-EPMC6956357 | biostudies-literature
Unknown Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
| S-EPMC8127964 | biostudies-literature
Unknown Crystal structures of two 6-(2-hy-droxy-benzo-yl)-5H-thia-zolo[3,2-a]pyrimidin-5-ones.
| S-EPMC4518966 | biostudies-literature
Unknown Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors.
| S-EPMC9325670 | biostudies-literature
Unknown <i>IDH1/2</i> Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.
| S-EPMC5884732 | biostudies-literature